Article
De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
Medicine - 22 Jul 2022
Ding Yingying, Dong Hongliang, Li YongCheng, Liu Lei, Cai Ying, Wang Ying, Tian Shengya, Dai Chengtao
Abstract excerpt
INTRODUCTION: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) mutations are the most common accurate gene targets. However, the lack of case reports or cohort studies on the exceptionally rare mutations limit the acquisition of deeper insights. PATIENT CONCERNS: A 76-year-old female nonsmoker presented to our hospital with a one-week disease...
Topics
Join the communities discussing this publication.